



January 22, 2024

California Institute for Regenerative Medicine (CIRM)
Application Number: CLIN2-15607

Re: Support for Elpida Therapeutics' Appeal regarding CIRM application CLIN2-15607

To Whom It May Concern,

I am writing to express my strong support for Elpida Therapeutics' appeal regarding their proposal (CLIN2-15607). This project aims to conduct a Phase 3 clinical trial for Spastic Paraplegia Type 50 (SPG50).

Our center possesses extensive experience in conducting clinical research and trials for neuropathic disorders including several funded by CIRM. I personally have an extensive experience with the diagnosis and management of hereditary spastic paraplegias. We are confident that our knowledge will prove invaluable for the intended trial involving genetic correction for SPG50.

Additionally, our clinical research coordinators and evaluators, alongside our physical therapists, have successfully carried out numerous complex therapeutic trials, including pathways that closely resemble the approach proposed for SPG50.

Thank you for considering our endorsement of Elpida Therapeutics' gene therapy trial proposal. We are committed to working together to advance the field and bring hope to patients affected by SPG50.

Yours Sincerely,

A handwritten signature in black ink, appearing to read 'T. Pierson', written in a cursive style.

Tyler Mark Pierson, MD-PhD
Assistant Professor
Departments of Pediatrics and Neurology &
the Board of Governors Regenerative Medicine Institute